Barry W. Hancock
University of Sheffield
312 Papers
2.6K Citations
Barry W. Hancock is an academic researcher from University of Sheffield. The author has contributed to research in topics: Medicine & Gestational trophoblastic disease. The author has an hindex of 53, co-authored 310 publications. Previous affiliations of Barry W. Hancock include Royal Hallamshire Hospital & Yorkshire Cancer Research.
Chat about Author
Papers
Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial
Dc Linch,D. A. Winfield,Ah Goldstone,D. Moir,Barry W. Hancock,A. McMillan,Rajesh Chopra,Donald Milligan,GV Hudson +8 more
TL;DR: A randomised comparison of high-dose chemotherapy plus ABMT with the same drugs at lower doses not requiring bone-marrow rescue in patients with active Hodgkin's disease found that high doses facilitated by ABMT can lead to better disease-free survival.
1K
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.
John Radford,Timothy M Illidge,Nicholas Counsell,Barry W. Hancock,R. Pettengell,Peter Johnson,Jennie Z Wimperis,Dominic Culligan,Bilyana Popova,Paul Smith,Andrew McMillan,Alison Brownell,Anton Kruger,Andrew Lister,Peter Hoskin,Michael O'Doherty,Sally F. Barrington +16 more
TL;DR: Patients with early-stage Hodgkin's lymphoma and negative PET findings after three cycles of ABVD had a very good prognosis either with or without consolidation radiotherapy, and the noninferiority of the strategy of no further treatment after chemotherapy with regard to progression-free survival did not show.
Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial.
Kirit M. Ardeshna,Paul Smith,Andrew J. Norton,Barry W. Hancock,Peter Hoskin,K. A. MacLennan,Robert Marcus,A.M. Jelliffe,G. Vaughan Hudson,David C. Linch +9 more
TL;DR: An initial policy of watchful waiting in patients with asymptomatic, advanced stage low-grade non-Hodgkin lymphoma is appropriate, especially in patients older than age 70 years.
539
Risk of Second Malignancy After Hodgkin’s Disease in a Collaborative British Cohort: The Relation to Age at Treatment
Anthony J. Swerdlow,J. A. Barber,GV Hudson,David Cunningham,R K Gupta,Barry W. Hancock,Alan Horwich,T. A. Lister,David C. Linch +8 more
TL;DR: Age at treatment has a major effect on risk of second malignancy after Hodgkin's disease and RRs of several important malignancies are much greater for patients who are treated when young, although absolute excess risks are greater for older patients.
504
Myocardial Infarction Mortality Risk After Treatment for Hodgkin Disease: A Collaborative British Cohort Study
Anthony J. Swerdlow,Craig D. Higgins,Paul Smith,David Cunningham,Barry W. Hancock,Alan Horwich,Peter Hoskin,Andrew Lister,John Radford,Ama Z. S. Rohatiner,David C. Linch +10 more
TL;DR: The risk of death from myocardial infarction after treatment for Hodgkin disease remains high for at least 25 years, and is related to supradiaphragmatic radiotherapy but may also be related to anthracycline and vincristine treatment.